Contemporary OB/GYN week in review: gonorrhea treatment, AI screening, and more

This week at Contemporary OB/GYN®, we covered topics ranging from the FDA's acceptance of gepotidacin for priority review to factors reducing HCV treatment odds. Click the links below to read anything you might have missed from Monday, August 11 to Friday, August 15, 2025.

FDA accepts gepotidacin for priority review for gonorrhea oral treatment

The FDA has accepted for priority review a supplemental New Drug Application (sNDA) for gepotidacin (Blujepa; GSK) as an oral treatment option for uncomplicated urogenital gonorrhea in patients aged 12 years and older weighing at least 45 kg, according to GSK. The Prescription Drug User Fee Act action date is December 11, 2025.

Recently, gepotidacin received FDA approval in March 2025 as an oral treatment for uncomplicated urinary tract infections (uUTI) in female adult and pediatric patients aged 12 years and older weighing at least 40 kg. Regulatory review for the uUTI indication is also underway in the United Kingdom and Australia.

GSK noted that this is the second major US regulatory submission for gepotidacin. “The FDA’s acceptance of our application for priority review reflects the potential of gepotidacin to address a significant unmet need in gonorrhea treatment,” the company stated.

Click here for the full article.

Top AI models show high accuracy in breast cancer screening

Artificial intelligence (AI) algorithms have shown high efficacy for identifying breast cancer on mammography images, according to a recent study published in Radiology on August 12, 2025.

These algorithms were submitted in the Radiological Society of North America’s (RSNA) AI Challenge, a crowdsourced competition with over 1500 participating teams. Of submissions, the best 10 showed a performance close to that of the average screening radiologist in Europe and Australia.

“We were overwhelmed by the volume of contestants and the number of AI algorithms that were submitted as part of the Challenge,” said Yan Chen, PhD, professor in cancer screening at the University of Nottingham. “…We were also impressed by the performance of the algorithms given the relatively short window allowed for algorithm development.”

Click here for the full article.

AI-based ultrasound model shows high accuracy in predicting delivery timing

A new artificial intelligence (AI) platform developed by Ultrasound AI has demonstrated high accuracy in predicting delivery timing from standard obstetric ultrasound images, according to findings from the Perinatal Artificial Intelligence in Ultrasound (PAIR) study published in The Journal of Maternal-Fetal & Neonatal Medicine. The study, conducted with researchers at the University of Kentucky, suggests the technology could improve risk assessment for preterm birth (PTB) and enhance maternal-fetal care, particularly in resource-limited settings.

“This is a major milestone for the field of maternal-fetal medicine and for Ultrasound AI,” said Robert Bunn, founder and president of Ultrasound AI. “Our AI’s ability to accurately predict delivery timing—and learn and improve over time—has profound implications for both clinical practice and public health, especially in settings where early risk identification is critical and access to specialist care is limited.”

Click here for the full article.

Sex and pregnancy linked to reduced HCV treatment odds in OUD patients

Risk factors of not receiving direct-acting antiviral (DAA) prescription among hepatitis C virus (HCV) patients entering opioid use disorder treatment include female sex and recent pregnancy, according to a recent study published in O&G Open.

The odds of being prescribed DAAs were significantly higher among men vs women, with rates of 40.6% for men, 35.7% for women without recent pregnancy, and 31.8% for women with recent pregnancy. Additionally, a hazard ratio (HR) for receiving HCV treatment of 1.19 was reported among men vs women.

When compared to women with recent pregnancy, men and women without pregnancy had adjusted HRs of 1.18 and 1.09, respectively, for receiving HCV treatment. Similar results were reported in a sensitivity analysis restricting the cohort to women with a pregnancy code at least 9 months before enrollment.

Click here for the full article.

Lower cervical cancer screening rates linked to higher late-stage diagnoses and mortality

Women living in US counties with persistently low cervical cancer screening rates experience nearly twice the rate of cervical cancer diagnoses, particularly of late-stage disease, and mortality compared with those in high-screening counties, according to a new analysis from researchers at the MUSC Hollings Cancer Center.

The study, published in JAMA Network Open, builds on prior work showing that cervical cancer incidence and death rates are higher in low-income and rural counties. “We know that higher screening uptake prevents disease and subsequent mortality,” said lead author Trisha Amboree, PhD. “In the previous papers, we didn't have any individual-level screening data. This paper helps to contextualize our previous findings to say what we're seeing is at least probably partially a result of repeatedly low screening.”

Click here for the full article.